Zydus Lifesciences Shares Climb After Licensing Deal with Synthon BV

iences Ltd. saw its share price rise by 0.79% to ₹1,020.00 on the BSE at 9:19 AM today, following the announcement of an exclusive licensing and supply agreement with Synthon BV of the Netherlands. The deal, secured through Zydus Lifesciences Global FZE, focuses on Ozanimod Capsules, a generic version of ZEPOSIA®, for the U.S. market. Synthon, which has a pending abbreviated new drug application with the U.S. FDA for Ozanimod Capsules (indicated for relapsing forms of multiple sclerosis), will handle regulatory approval and manufacturing. Zydus will oversee commercialization in the U.S. The total addressable market for Ozanimod Capsules is estimated at $637 million, per IQVIA MAT July 2025 data. This collaboration strengthens Zydus’ position in the U.S. pharmaceutical market, emphasizing its commitment to accessible healthcare solutions.